home / stock / imv:cc / imv:cc news

IMV:CC News and Press, Imv Inc. From 11/08/22

Stock Information
Company Name: Imv Inc.
Stock Symbol: IMV:CC
Market: TSXC
Website: imv-inc.com
Menu
IMV:CC IMV:CC Quote IMV:CC Short IMV:CC News IMV:CC Articles IMV:CC Message Board
Get IMV:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
IMV:CC - IMV Inc. to Announce Third Quarter 2022 Results and Host a Conference Call and Webcast on November 11, 2022

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Friday, November 11, 2022...
IMV:CC - IMV Provides an Update on The VITALIZE Trial

Enrollment has accelerated in the last quarter, reflecting enthusiasm for this novel treatment option Data to be presented at a scientific conference in early 2023 IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of ...

IMV:CC - IMV Inc. Announces Strategic Reorganization

Reorganization enhances organizational focus on strategic priorities Clinical update on DLBCL patients in Phase 2B VITALIZE trial to be provided in September Appointment of Dr. Saman Maleki to Board of Directors Brittany Davison promoted to Chief Accounting Off...

IMV:CC - IMV Inc. to Present at Two Investor Conferences in September

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced that members of IMV’s executive management team will be presenting at...
IMV:CC - IMV Inc. Announces Second Quarter 2022 Financial and Operational Results

Patient recruitment in the Phase 2B VITALIZE DLBCL trial of MVP-S plus Keytruda continues to track well, with first results expected in Q3 2022. Matthew J. Matasar, MD from Memorial Sloan Kettering Cancer Center, has joined VITALIZE as lead principal investigator of the study. ...

IMV:CC - IMV Re-Establishes Its At-the-Market Facility Under Renewed Base Shelf Prospectus

IMV Inc. (“ IMV ” or the “ Company ”) (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced that it pla...

IMV:CC - IMV Inc. to Announce Second Quarter 2022 Results and Host a Conference Call and Webcast on August 11, 2022

IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that it will hold a conference cal...
IMV:CC - IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

IMV Inc. (“ IMV ” or the “ Company ”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ™ platform to treat solid and hematologic cancers, today announced that on J...

IMV:CC - IMV Announces Annual and Special Meeting of Shareholders Voting Results

IMV Inc. (“ IMV ” or the “ Company ”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced the voting ...

IMV:CC - IMV Strengthens Its Financial Position With the $US10 Million Drawdown From Its Existing Long-Term Debt Facility

IMV achieves predetermined milestone to access the remaining $US10 Million under its Debt Facility with Horizon Phase 2b AVALON trial in platinum-resistant ovarian cancer open for enrollment IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a ...
Previous 10 Next 10